LHCVX Mutual Fund

NAV$24.02
Showing 10 of 64 holdings(as of Apr 30, 2026)Top 10 Weight: 37.55%
#TickerNameWeightSharesMkt ValueShare ChgPROSectorPROIndustryPRO
1LLYEli Lilly And Company8.89%775$724.3K-Health CarePharmaceuticals
2AZN:LNAstrazeneca Plc Adr4.73%2,029$384.9K+183UnknownUnknown
3GILDGilead Sciences Inc4.25%2,647$346.3KProProPro
4JNJJOHNSON AND JOHNSON3.19%1,129$259.5KProProPro
5NKTRNektar Therapeutics3.17%3,038$258.4KProProPro
6NTRANatera Inc2.91%1,151$237.3KProProPro
7TARSTarsus Pharmaceuticals Inc2.83%3,622$230.4KProProPro
8GHGuardant Health Inccommon Stock2.63%2,459$214.1KProProPro
9ARGX:ASArgenx Se (Brussels Stock Exchange)2.49%259$203.1KProProPro
10NOVN:SMNovartis Ag Ordinary Shares2.46%1,356$200.4KProProPro
See the other 54 holdings of LHCVX
Every position with sector, industry and share changes, as reported Apr 30, 2026.
Get FundXLS Pro: $29/moFirst 500 subscribers, then $49/mo. Cancel anytime.

Top Holdings Themes

PharmaceuticalsBiotechnologyImmunologyOncologyMedical DevicesLife Sciences ToolsDigital Health

LHCVX Mutual Fund Top Holdings

LHCVX holdings top 10 positions. The top 10 holdings account for 37.6% of the fund, led by Eli Lilly And Company at 8.9%, Astrazeneca Plc Adr at 4.7%, Gilead Sciences Inc at 4.3%.

LHCVX portfolio concentration is moderate, with the top 10 representing 37.6% of total assets. The largest sector exposure is Health Care at 80.2%.

LHCVX sector allocation provides a detailed breakdown. LHCVX overlap tool shows how holdings compare to other funds in your portfolio.